Singapore: Mr Chris Fullerton, chairman of Australian firm Bionomics, will retire from the board of Bionomics, effective December 31, 2012. The directors have agreed that, following confirmation of his board appointment at the company's annual general meeting to be held on November 14, 2012, Mr Graeme Kaufman will assume the chairmanship of Bionomics.

"It has been a great privilege to chair a drug discovery and development company of the quality and international standing of Bionomics. The high level of commitment, professionalism and integrity displayed by Deborah Rathjen and her talented management team is second to none. Further, our Board has an enviable depth of international industry and financial experience to support our growth strategy," said Mr Fullerton.

Mr Fullerton added that "Graeme has both detailed biotech management experience and a global exposure to investors and industry contacts that make him ideally qualified to chair Bionomics, as the company further internationalizes its business, presence and shareholder base."

"I welcome the opportunity to take a leadership role within Bionomics. The last three years under Chris Fullerton's stewardship has seen a transformation in the Company, building a solid base for the next exciting growth phase of our development. We thank Chris for his significant contributions and wish him all the best in his new ventures," said Mr Kaufman.